google-site-verification: googlef34d17771a9ef049.html Blog | cba-consulting
  • LinkedIn Social Icon

© 2017 by Cambridge Biostrategy Associates LLC. Proudly created with Wix.com

Please reload

Follow Us

But along with enthusiasm in areas as diverse as phenotypic screening, drug repositioning, and CT analysis, we are also finding a growing skepticism: what is real and what is hype? An example often cited by skeptical clients are the problems surrounding IBM Watson Heal...

February 6, 2018

Butterfly Networks announced their Butterfly iQ product for release in the Spring of 2018.  The iPhone-based product is expected to democratize ultrasound with its sub $2,000 price point.  Because of Ultrasound’s current cost and complexity, most imaging today is done...

September 19, 2017

In my previous blog post, I suggested that the market size for gene-modified T-cell therapies would be roughly $9 Bn in 10 years, with a range of around $5 - $20 Bn. In this post I will provide some structure for this wide range by breaking out five key factors that wi...

September 13, 2017

Over the last two months, several news events have brought CAR-T cells to widespread public attention, the most prominent of which is the FDA approval of the first gene-modified cell therapy, for children with a type of leukemia who have failed other options. The new t...

September 7, 2017

I’ve been involved with Digital Health since 2012. At that time, the industry was espousing how Digital Health was ready to explode – applications were going to be prescribed by physicians; men, women, and children would readily adopt these solutions as they had Facebo...

September 5, 2017

In the NY Times article, “Take the Generic, Patients Are Told. Until They Are Not.”, Pharmacy Benefit Managers (PBMs) were called out for pushing branded products over generics to patients.

PBMs are primarily responsible for developing and maintaining the formulary, con...

Please reload

  • LinkedIn Social Icon